Highly bioavailable nasal calcitonin - Potential for expanded use in analgesia

Drug Delivery Technology

Volumn 10, Issue 1, 2010, Pages 58-63

  Maggio, Edward T ^a,b   Meezan, Elias ^c   Ghambeer, D K S ^d   Pillion, Dennis J ^e  

^a Aegis Therapeutics

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Apothecaries Limited   (India)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SALCATONIN;

ADULT; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION;

EID: 75749153676     PISSN: 15372898     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (32)

1. Franceschini R, Cataldi A, Cianciosi P, Garibaldi A, Corsini G, Barreca T, Rolandi E. Calcitonin and beta-endorphin secretion. Biomed Pharmacother. 1993;7:305-309.
2. Blau LA, Hoehns JD. Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother. 2003;37:564-570.
3. Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH. Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int. 2005;16:1281-1290.
4. Konno S, Kikuchi S. Therapeutic effects of calcitonin on back pain in the patients with osteoporosis. Clin Calcium. 2005;15:168-173.
5. Tanaka K, Yoshizawa M, Yoh K. Improvement of QOL in osteoporotic patients by calcitonin treatment. Clin Calcium. 2005;15:174-178.
6. Laroche M, Cantogrel S, Jamard B, et al. Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. Clin Rheumatol. 2006;25:683-686.
7. Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol. 2007;26:44-49.
8. Hindley AC, Hill EB, Leyland MJ, Wiles AE. A double-blind controlled trial of salmon calcitonin in pain due to malignancy. Cancer Chemother Pharmacol. 1982;9:71-74.
9. Allan E. Calcitonin in the treatment of intractable pain from advanced malignancy. Pharmatherapeutica. 1983;3:482-486.
10. Egawa J, Kawada Y, Abe M, et al. Effect of porcine calcitonin on pain caused by cancer-induced bone destruction. Gan No Rinsho. 1984;30:251-258.
11. Hirota Y, Kondou S, Okamura H, et al. Effectiveness of synthetic calcitonin derivative (elcatonin) on the bone pain and serum calcium concentration in multiple myeloma. Gan To Kagaku Ryoho. 1990;17:1059-1063.
12. Szanto J, Ady N, Jozsef S. Pain killing with calcitonin nasal spray in patients with malignant tumors. Oncol. 1992;49:180-182.
13. Jelic S, Borkovacki R, Babovic N, Kovcin V, Milanovic N. Antipain effect of salmon calcitonin in bone metastases of malignant tumors with the exception of breast and prostatic carcinoma. Vojnosanit Pregl. 1995;52:151-154.
14. Mystakidou K, Befon S, Hondros K, Kouskouni E, Vlahos L. Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: pain control and beta-endorphin plasma levels. J Pain Symptom Manage. 1999;18:323-330.
15. Simanski C, Lempa M, Koch G, Tiling T, Neugebauer E. Therapy of phantom pain with salmon calcitonin and effect on postoperative patient satisfaction Chirurg. 1999;70:674-681.
16. Wall GC, Heyneman CA. Calcitonin in phantom limb pain. Ann Pharmacother. 1999;33:499-501.
17. Jaeger H, Maier C, Wawersik J. Postoperative treatment of phantom pain and causalgias with calcitonin. Anaesthesist. 1988; 37:71-76.
18. Jaeger H, Maier C. Calcitonin in phantom limb pain: a double-blind study. Pain. 1992;48:21-27.
19. Quevedo SF. Use of calcitonin in sickle cell bone crisis. Blood. 1996;88:1520.
20. Qin H, Cai J, Yang FS. Could calcitonin be a useful therapeutic agent for trigeminal neuralgia? Med Hypotheses. 2008;71:114-116.
21. Novartis. Miacalcin Nasal Spray Package Insert. Available from http://www.fda.gov/medwAtch/SAFETY/2006/Jan-PI/Miacalcin-PI.pdf. Accessed April 15, 2009.
22. Pillion DJ, Atchison JA, Gargiulo C, Wang RX, Wang P, Meezan E. Insulin delivery in nosedrops: new formulations containing alkylglycosides. Endocrinol. 1994;135:2386-2391.
23. Pillion DJ, Atchison JA, Stott J, McCracken D, Gargiulo C, Meezan E. Efficacy of insulin eyedrops. J Ocul Pharmacol. 1994;10:461-470.
24. Pillion DJ, Hosmer S, Meezan E. Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: independence of surfactant action from multimer dissociation. Pharm Res. 1998;15:1637-1639.
25. Ahsan F, Arnold J, Meezan E, Pillion DJ. Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats. Pharm Res. 2001;18:1742-1746.
26. Arnold J, Ahsan F, Meezan E, Pillion DJ. Nasal administration of low molecular weight heparin. J Pharm Sci. 2002;91:1707-1714.
27. Pillion DJ, Ahsan F, Arnold JJ, Balusubramanian BM, Piraner O, Meezan E. Synthetic long-chain alkyl maltosides and alkyl sucrose esters as enhancers of nasal insulin absorption. J Pharm Sci. 2002;91:1456-1462.
28. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci. 2004;93:2205-2213.
29. Hussain A, Yang T, Zaghloul AA, Ahsan F. Pulmonary absorption of insulin mediated by tetradecyl-beta-maltoside and dimethyl-beta-cyclodextrin. Pharm Res. 2003;20:1551-1557.
30. Weber N, Benning H. Metabolism of orally administered alkyl beta-glycosides in the mouse. J Nutr. 1984;114:247-254.
31. Rafferty B, Corran P, Bristow A. Multicenter collaborative study to calibrate salmon calcitonin by bioassay and high-performance liquid chromatography: establishment of the third international standard. Bone. 2001;29(1):84-89.
32. Sinswat P, Tengamnuay P. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins. Int J Pharm. 2003;257:15-22.